Index to Volume 28

Author Index

- A -

Abdulhamid I, Wise TL, Andrews S, Biglin K, Lehr VT: Elevated Serum Tobramycin Concentrations After Treatment with Tobramycin Inhalation in a Preterm Infant, 939

AbuTarif M: see Krishna G, et al, 1223

ACCP: 2008 Annual Meeting Abstracts and Index of Authors, 115e, 1309

ACCP: 2008 Spring Practice and Research Forum: Updates in Therapeutics/Updates In Therapeutics Abstracts and Index of Authors, 37e, 552

ACCP, Burke JM, Miller WA, Spencer AP, Crank CW, Adkins L, Bertch KE, Ragucci DP, Smith WE, Valley AW: Clinical Pharmacist Competencies, 806

ACCP, Cheang KI, Ott C, Garner S, Campbell H, Hansen L, Ma Q, Nazeri E, Gunning K, Wermeling D: Research in Women and Special Populations, 93e, 1203

ACCP, Haase KK, Smythe MA, Orlando PL, Resman-Targoff BH, Smith LS: Quality Experiential Education, 219e, 1547

ACCP, Haase KK, Smythe MA, Orlando PL, Resman-Targoff BH, Smith LS: Ensuring Quality Experiential Education, 1548

ACCP, Harris IM, Baker E, Berry TM, Halloran MA, Lindauer K, Ragucci KR, McGivney MS, Taylor AT, Haines ST: Developing a Business-Practice Model for Pharmacy Services in Ambulatory Settings, 7e, 285

ACCP, Klepser ME, Matzke GR, Vivian E, Granberry M, Majerus T, Wiggins B, Hill-Zabala C, Weimert N, Raebel MA: Ethical Issues Related to Clinical, Translational, and Health System Research, 229e, 1421

ACCP: Pharmacists and Industry: Guidelines for Ethical Interactions, 410

ACCP: The Definition of Clinical Pharmacy, 816

Acosta EP: see Ofotokun I, et al, 74

Adkins L: see ACCP, et al, 806

Ageno W: see Clark NP, et al, 960

Airee A, Draper HM, Finks SW: Aspirin Resistance: Disparities and Clinical Implications, 999

Alaniz C: see Btaiche IF, et al, 600

Alexander GC: see Walton SM, et al, 1443

Al-Mondhiry HA: see Young SK, et al, 1531

Altshuler M: see Studdiford J, et al, 1194

Alvarez C: see Edwards KL, et al, 506

Amankwa K: see Tisdale JE, et al, 1461

Ambrose A: see Young SK, et al, 1531

Ambrosini MT: Autoimmunity and Schizophrenia, 217e

Ambuehl R: see Hansen RA, et al, 1325

Amrutkar P: see Garey KW, et al, 699

Amur S: see Frueh FW, et al, 992

Anderson GD: see Eberly AL, et al, 1502

Andrade SE: see Briesacher BA, et al, 437

Andrews S: see Abdulhamid I, et al, 939

Angulo D: see Krishna G, et al, 1223

Arab-Alameddine M: see Csajka C, et al, 215e

Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ: Continued Challenges with the Use of Erythropoiesis-Stimulating Agents in Patients with Cancer: Perspectives and Issues on Policy-Guided Health Care, 1S

Archer SM: see Miller JL, et al, 875

Ardery G: see Milchak JL, et al, 843

Arpino PA, Greer DM: Practical Pharmacologic Aspects of Therapeutic Hypothermia After Cardiac Arrest, 102

Arria AM, Caldeira KM, O'Grady KE, Vincent KB, Johnson EP, Wish ED: Nonmedical Use of Prescription Stimulants Among College Students: Associations with Attention-Deficit–Hyperactivity Disorder and Polydrug Use, 156

Asare K: Anemia of Critical Illness, 1267

Ashford JW: see Miller JL, et al, 875

Ateshkadi A: see Munger MA, et al, 834

Atkinson S: see Metz DC, et al, 301

Aubert RE: see Frueh FW, et al, 992

- B -

Baetz BE, Spinler SA: Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases, 1354

Bain AM, White EA, Rutherford WS, Rahman AP, Busti AJ: A Multimodal, Evidence-Based Approach to Achieve Lipid Targets in the Treatment of Antiretroviral-Associated Dyslipidemia: Case Report and Review of the Literature, 932

Bain AM: see Nguyen ST, et al, 323

Bain AM: see Rahman AP, et al, 913

Bainbridge JL: see Page RL II, et al, 271

Baker E: see ACCP, et al, 7e, 285

Bakst AW: see Kane-Gill S, et al, 269e, 1552

Ball AM, Winstead PS: Recombinant Human Erythropoietin Therapy in Critically Ill Jehovah's Witnesses, 1383

Balu RB: see Cohen CJ, et al, 314

Baringhaus SN: see Garwood CL, et al, 20

Barnes CA: see Delate T, et al, 444

Barone JA: see Boyce EG, et al, 245e

Barri YM: see Munger MA, et al, 834

Barriere SL: see Laohavaleeson S, et al, 1471

Bauer SR: see Lam SW, et al, 591

Bearden DT: see Touchette DR, et al, 584

Becker RC: see Pickard AS, et al, 376
Bedimo R: see Nguyen ST, et al, 323
Bedimo R: see Rahman AP, et al, 913
Berdine HJ: see Herndon CM, et al, 788
Bergus GR: see Fravel MA, et al, 1341
Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B: Lack of Effect of P-glycoprotein Inhibition on Renal Clearance of Dicloxacillin in Patients with Cystic Fibrosis, 883
Berry TM: see ACCP, et al, 7e, 285
Bertch KE: see ACCP, et al, 806
Bertino JS Jr: see Hameed MS, et al, 707
Bestul DJ: see Reeves DJ, et al, 685
Biaglow MA: see Lutomski DM, et al, 1348
Bigelow GE: see Cao Y-J, et al, 863
Biglin K: see Abdulhamid I, et al, 939
Bishop J: see Kissack JC, et al, 769
Blouin R: see Figg WD, et al, 821
Boffito M: see Schöller-Gyüre M, et al, 1215
Bogdan GM: see Green JL, et al, 453
Bond CA, Raehl CL: 2006 National Clinical Pharmacy Services Survey: Clinical Pharmacy Services, Collaborative Drug Management, Medication Errors, and Pharmacy Technology, 1
Borja NL: see Ramirez MA, et al, 646
Borzak S: see Tisdale JE, et al, 1461
Botti JJ: see Young SK, et al, 1531
Boyce EG, Burkiewicz JS, Haase MR, MacLaughlin EJ, Segal AR, Chung EP, Chan L-N, Rospond RM, Barone JA, Durst SW, Wells BG: Essential Components of a Faculty Development Program for Pharmacy Practice Faculty, 245e
Brachman PS: see Cohen CJ, et al, 314
Brandt JT: see Farid NA, et al, 1483
Bream-Rouwenhorst HR, Hobbs RA: Heparin-Dependent Antibodies and Thrombosis without Heparin-Induced Thrombocytopenia, 1401
Brieke AA: see Page RL II, et al, 271
Brielmaier BD, Casabar E, Kurtzeborn CM, McKinnon PS, Ritchie DJ: Early Clinical Experience with Anidulafungin at a Large Tertiary Care Medical Center, 64
Briesacher BA, Andrade SE, Fouayzi H, Chan KA: Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions, 437
Bring P, Partovi N, Ford JE, Yoshida EM: Iron Overload Disorders: Treatment Options for Patients Refractory to or Intolerant of Phlebotomy, 331
Brophy DF: see Maynor LM, et al, 977
Brown RO: see Dickerson RN, et al, 308
Brubaker CM: see Wilhelm SM, et al, 496
Btaiche IF, Mohammad RA, Alaniz C, Mueller BA: Amino Acid Requirements in Critically Ill Patients with Acute Kidney Injury Treated with Continuous Renal Replacement Therapy, 600
Buadi FK: see Przepiorka D, et al, 58
Bubalo JS: see Eberly AL, et al, 1502
Buck ML, Willson DF: Use of Dexmedetomidine in the Pediatric Intensive Care Unit, 51
Buclin T: see Csajka C, et al, 215e
Burch JC: see Kiser TH, et al, 1115
Burckart GJ: see Beringer PM, et al, 883
Burckart GJ: see Frueh FW, et al, 992
Burke JM: see ACCP, et al, 806
Burkiewicz JS: see Boyce EG, et al, 245e
Bussey HI, Wittkowsky AK, Hylek EM, Walker MB: Genetic Testing for Warfarin Dosing? Not Yet Ready for Prime Time, 141
Busti AJ: see Bain AM, et al, 932
Busti AJ: see Nguyen ST, et al, 323
Busti AJ: see Rahman AP, et al, 913
Butler KL: see Onofrei MD, et al, 522

- C -

Caballero J: see Marino J, et al, 1283
Cahoon W: see Crouch MA, et al, 1413
Caldeira KM: see Arria AM, et al, 156
Calmy A: see Csajka C, et al, 215e
Campagna E: see Green JL, et al, 453
Campbell H: see ACCP, et al, 93e, 1203
Cao Y-J, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW: Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Fosamprenavir-Ritonavir in Opioid-Dependent Subjects, 863
Caputi AP: see Oteri A, et al, 549
Carl DE: see Maynor LM, et al, 977
Carter BL: Preventing Thiazide-Induced Hyperglycemia: Opportunities for Clinical Pharmacists, 1425
Carter BL: see Fravel MA, et al, 1341
Carter BL: see Milchak JL, et al, 843
Carter BL: see Weber CA, et al, 1104
Carver PL: see Surowiec D, et al, 719
Casabar E: see Brielmaier BD, et al, 64
Catania MA: see Oteri A, et al, 549
Causon RC: see Cao Y-J, et al, 863
Cavassini M: see Csajka C, et al, 215e
Cha R: In Vitro Activity of Cefepime, Imipenem, Tigecycline, and Gentamicin, Alone and in Combination, Against Extended-Spectrum β-Lactamase–Producing *Klebsiella pneumoniae* and *Escherichia coli*, 295
Cha SS: see Lam SW, et al, 591
Chan KA: see Briesacher BA, et al, 437
Chan L-N: see Boyce EG, et al, 245e
Chapman SA: see Lewandowski MJ, et al, 1542
Chase SL: see Kintzel PE, et al, 1511
Chau CH: see Figg WD, et al, 821
Cheang KI: see ACCP, et al, 93e, 1203
Cheatham SC, Kays MB, Smith DW, Wack MF, Sowinski KM: Steady-State Pharmacokinetics and Pharmacodynamics of Meropenem in Hospitalized Patients, 691
Chen H: see Garey KW, et al, 699
Chen JT: see Herndon CM, et al, 788

Chester EA: see Delate T, et al, 444
Cheung AK: see Munger MA, et al, 834
Choy CK, Rodgers JE, Nappi JM, Haines ST: Type 2 Diabetes Mellitus and Heart Failure, 170
Chung EP: see Boyce EG, et al, 245e
Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA: Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study, 960
Clay PG: Research Publications by Pharmacists: Kudos and Questions, 91e
Coffee AL, Kuehl TJ, Sulak PJ: Comparison of Scales for Evaluating Premenstrual Symptoms in Women Using Oral Contraceptives, 576
Cohen CJ, Kubota M, Brachman PS, Harley WB, Schneider S, Williams VC, Sutherland-Phillips DH, Lim ML, Balu RB, Shaefer MS: Short-term Safety and Tolerability of a Once-Daily Fixed-Dose Abacavir-Lamivudine Combination versus Twice-Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study, 314
Cohen J: see Figg WD, et al, 821
Cooper T: see Mohr J, et al, 614
Coram R: see Tisdale JE, et al, 1461
Corbett SM, Montoya ID, Moore FA: Propofol-Related Infusion Syndrome in Intensive Care Patients, 250
Cordero L: see Schneider JK, et al, 1335
Cornely OA: see Krishna G, et al, 1223
Correll T, Klibanov OM: Integrase Inhibitors: A New Treatment Option for Patients with Human Immunodeficiency Virus Infection, 90
Crank CW: see ACCP, et al, 806
Crookes BA: see Murphy CE, et al, 968
Crouch MA, Kasirajan V, Cahoon W, Katlaps GJ, Gunnerson KJ: Successful Use and Dosing of Bivalirudin After Temporary Total Artificial Heart Implantation: A Case Series, 1413
Crownover PH: see Fang AF, et al, 42
Crowther MA: see Clark NP, et al, 960
Csajka C, Cavassini M, Rotger M, Decosterd LA, Furrer H, Calmy A, Fayet A, Arab-Alameddine M, Widmer N, Iulio J, Telenti A, Buclin T: Efavirenz Dose Adjustment in HIV Patients with Impaired CYP2B6 Function, 215e
Custer G: see Daly MW, et al, 1408

- D -

Daly MW, Custer G, McLeay PD: Cardiac Arrest with Pulseless Electrical Activity Associated with Methylphenidate in an Adolescent with a Normal Baseline Echocardiogram, 1408
Damle BD: see Fang AF, et al, 42
Dang D: see Herndon CM, et al, 788
Dao-Tran TK: see Garey KW, et al, 699
Dart RC: see Green JL, et al, 453
Dawson JD: see Fravel MA, et al, 1341
Dawson JD: see Milchak JL, et al, 843
de Denus S: see Gaffney SM, et al, 1041
Decosterd LA: see Csajka C, et al, 215e
Delate T, Chester EA, Stubbings TW, Barnes CA: Clinical Outcomes of a Home-Based Medication Reconciliation Program After Discharge from a Skilled Nursing Facility, 444
Delate T: see Clark NP, et al, 960
DeLuca TM: see Frueh FW, et al, 992
DePestel DD: see Surowiec D, et al, 719
Devlin JW: see Lancaster JW, et al, 852
Devlin JW: see Metz DC, et al, 301
Dickerson LM: see Shrader SP, et al, 1033
Dickerson RN, Garmon WM, Kuhl DA, Minard G, Brown RO: Vitamin K–Independent Warfarin Resistance After Concurrent Administration of Warfarin and Continuous Enteral Nutrition, 308
Doll MA: see Kennedy MJ, et al, 1495
Doloresco F, Vermeulen LC: Insufficient Evidence of Equivalence—Alternate Dosing of Meropenem, 4e
Doloresco F: see Perez A, et al, 285e
Donaldson AR: see Hornsby LB, et al, 536
Doron SI: see Lancaster JW, et al, 852
Draper HM: Depressive Disorder Associated with Mycophenolate Mofetil, 136
Draper HM: see Airee A, et al, 999
Dumo P: see Garwood CL, et al, 20
Durst SW: see Boyce EG, et al, 245e

- E -

Easley KA: see Ofotokun I, et al, 74
Eaton SA: see Nguyen ST, et al, 323
Eaton SA: see Rahman AP, et al, 913
Eberly AL, Anderson GD, Bubalo JS, McCune JS: Optimal Prevention of Seizures Induced by High-Dose Busulfan, 1502
Edmond M: see Pakyz A, et al, 906
Edwards KL, Alvarez C, Irons BK, Fields J: Third-Line Agent Selection for Patients with Type 2 Diabetes Mellitus Uncontrolled with Sulfonylureas and Metformin, 506
Ensom MHH: see Ensom RJ, et al, 88e
Ensom RJ, Ensom MHH: Will Genetic Testing for Warfarin Dosing Ever be Ready for Prime Time?, 88e
Epstein RS: see Frueh FW, et al, 992
Ernest CS II: see Farid NA, et al, 1483
Ernst ME: see Fravel MA, et al, 1341
Erstad BL: see Patanwala AE, et al, 1453
Essien EJ: see Garey KW, et al, 699

- F -

Fang AF, Damle BD, LaBadie RR, Crownover PH, Hewlett D Jr, Glue PW: Significant Decrease in Nelfinavir Systemic Exposure After Omeprazole Coadministration in Healthy Subjects, 42
Fanos V: see Zaffanello M, et al, 125
Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS II, Salazar DE, Konkoy CS, Winters KJ: Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects, 1483

Farnsworth DD: see Herndon CM, et al, 788
Farris KB: see Weber CA, et al, 1104
Farthing C: see Maynor LM, et al, 977
Farthing D: see Maynor LM, et al, 977
Fayet A: see Csajka C, et al, 215e
Fermo JD: see Herndon CM, et al, 788
Ferrentino N: see Murphy CE, et al, 968
Fields J: see Edwards KL, et al, 506
Figg WD, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed M, Pieper J, Knoell D, Miller K, Speedie M, Blouin R, Kroboth P, Koda-Kimble MA, Taylor P, Cohen J, Giacomini K: Pathways to Biomedical Research: The National Institutes of Health Special Conference on Pharmacy Research, 821
Finch CK: see Usery JB, et al, 1183
Fink J: see Nappi J, et al, 819
Fink JL III: see Romanelli F, et al, 1429
Finks SW: see Airee A, et al, 999
Flaig TW: see O'Bryant CL, et al, 1071
Fletcher CV: see Torno MS, et al, 782
Flockhart DA: see Tisdale JE, et al, 1461
Fong JJ: see Lancaster JW, et al, 852
Ford JE: see Bring P, et al, 331
Forsyth LL, Liu-DeRyke X, Parker D Jr, Rhoney DH: Role of Hypertonic Saline for the Management of Intracranial Hypertension After Stroke and Traumatic Brain Injury, 469
Fosnight SM, Zafirau WJ, Hazelett SE: Vitamin D Supplementation to Prevent Falls in the Elderly: Evidence and Practical Considerations, 225
Fouayzi H: see Briesacher BA, et al, 437
Franchini M: see Zaffanello M, et al, 125
Franciscus CL: see Milchak JL, et al, 843
Fraser GL: see Yahwak JA, et al, 984
Fravel MA, Ernst ME, Weber CA, Dawson JD, Carter BL, Bergus GR: Influence of Patient Characteristics on Success of Ambulatory Blood Pressure Monitoring, 1341
Frazee LA: see Gallegos PJ, et al, 356
Freiburg CB: see Murphy CE, et al, 968
Frost CP: see Garey KW, et al, 699
Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, Verbrugge RR, Burckart GJ, Lesko LJ: Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use, 992
Frye CB: see Pickard AS, et al, 376
Fuchs EJ: see Cao Y-J, et al, 863
Fuchs T, Groysman R, Meilichov I: Use of a Combination of Class III and Class Ic Antiarrhythmic Agents in Patients with Electrical Storm, 14
Fuke DC: see Onofrei MD, et al, 522
Furrer H: see Csajka C, et al, 215e

- G -

Gaffney SM, de Denus S, Olson KL, Ripley TL, Robinette B, Summers KM, Spencer AP: Key Articles and Guidelines in the Management of Hypertension: 2008 Update, 1041
Gallegos PJ, Frazee LA: Anticholinergic Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 356
Gallegos PJ, MacLaughlin EJ, Haase KK: Serial Monitoring of Brain Natriuretic Peptide Concentrations for Drug Therapy Management in Patients with Chronic Heart Failure, 343
Garcia D: see Clark NP, et al, 960
Gardner DK: see Schneider JK, et al, 1335
Gardner SF: see Munger MA, et al, 834
Garey KW, Amrutkar P, Dao-Tran TK, Frost CP, Chen H, Essien EJ, Gentry LO: Economic Benefit of Appropriate Timing of Vancomycin Prophylaxis in Patients Undergoing Cardiovascular Surgery, 699
Garmon WM: see Dickerson RN, et al, 308
Garner J: see Owen P, et al, 259
Garner S: see ACCP, et al, 93e, 1203
Garpestad E: see Lancaster JW, et al, 852
Gartung AM: see Hameed MS, et al, 707
Garwood CL, Dumo P, Baringhaus SN, Laban KM: Quality of Anticoagulation Care in Patients Discharged from a Pharmacist-Managed Anticoagulation Clinic After Stabilization of Warfarin Therapy, 20
Gasse C, Jacobsen J, Pedersen L, Mortensen PB, Nørgaard M, Sørensen HT, Johnsen SP: Risk of Hospitalization for Acute Pancreatitis Associated with Conventional and Atypical Antipsychotics: A Population-Based Case-Control Study, 27
Gehr TWB: see Maynor LM, et al, 977
Gentry LO: see Garey KW, et al, 699
Gerhard T, Zineh I, Winterstein AG, Hartzema AG: Uncertain Economic Impact of Nesiritide in Advanced Decompensated Heart Failure, 1e
Giacomini K: see Figg WD, et al, 821
Ginzburg R: see See S, et al, 207
Giustini SE: see Oteri A, et al, 549
Glue PW: see Fang AF, et al, 42
Goldsmith C-AW, Rogers DP: The Case for Autoimmunity in the Etiology of Schizophrenia, 730
Goldstein MR: see Mascitelli L, et al, 35e
Golik MV, Lawrence KR: Comparison of Dosing Recommendations for Antimicrobial Drugs Based on Two Methods for Assessing Kidney Function: Cockcroft-Gault and Modification of Diet in Renal Disease, 1125
Gong WC: Determining Effective Insulin Analog Therapy Based on the Individualized Needs of Patients with Type 2 Diabetes Mellitus, 1299
Goodsaid FM: Modulation of Clopidogrel Pharmacodynamic Response, 1423
Granberry M: see ACCP, et al, 229e, 1421
Green JL, Campagna E, Bogdan GM, Dart RC, Heard K: Effects of Clinical Laboratory Choice on Study Outcome: An Interlaboratory Evaluation of Aminotransferase Levels, 453
Greer DM: see Arpino PA, et al, 102

Grice GR, Mertens MK: Gabapentin as a Potential Option for Treatment of Sciatica, 397
Griffin AR: see Kennedy MJ, et al, 1495
Griffith NL: see Arbuckle RB, et al, 1S
Groysman R: see Fuchs T, et al, 14
Gunnerson KJ: see Crouch MA, et al, 1413
Gunning K: see ACCP, et al, 93e, 1203
Gupta SR: see Kane-Gill S, et al, 269e, 1552
Gutierrez MJ: see Taylor MB, et al, 712

- H -

Haase K: see Nappi J, et al, 819
Haase KK: see ACCP, et al, 1548
Haase KK: see ACCP, et al, 219e, 1547
Haase KK: see Gallegos PJ, et al, 343
Haase MR: see Boyce EG, et al, 245e
Haglund LA: see Lutomski DM, et al, 1348
Haines ST: see ACCP, et al, 7e, 285
Haines ST: see Choy CK, et al, 170
Halloran MA: see ACCP, et al, 7e, 285
Halterman PA: Lapatinib and Ixabepilone for the Treatment of Metastatic Breast Cancer, 1255
Hameed MS, Nafziger AN, Gartung AM, Bertino JS Jr: Pharmacodynamics of Uniform versus Nonuniform Warfarin Dosages, 707
Hammon JW Jr: see Reichert MG, et al, 151
Hansen L: see ACCP, et al, 93e, 1203
Hansen LB: see Miller AE, et al, 553
Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD: Risk of Adverse Gastrointestinal Events from Inhaled Corticosteroids, 1325
Harik N: see O'Brien CE, et al, 1059
Harkins M: see Raissy HH, et al, 287
Harley WB: see Cohen CJ, et al, 314
Harmston M: see Milchak JL, et al, 843
Harpe SE: see Pakyz A, et al, 906
Harper DM: see Zimmerman JJ, et al, 895
Harris IM: see ACCP, et al, 7e, 285
Hartzema AG: see Gerhard T, et al, 1e
Hassell KL: see Kiser TH, et al, 1115
Hazelett SE: see Fosnight SM, et al, 225
Heard K: see Green JL, et al, 453
Hebert JC: see Murphy CE, et al, 968
Hein DW: see Kennedy MJ, et al, 1495
Hendrix CW: see Cao Y-J, et al, 863
Hergott L: see Owen P, et al, 259
Herndon CM, Hutchison RW, Berdine HJ, Stacy ZA, Chen JT, Farnsworth DD, Dang D, Fermo JD: Management of Chronic Nonmalignant Pain with Nonsteroidal Antiinflammatory Drugs: Joint Opinion Statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy, 788
Herrington JD: see Nguyen ST, et al, 323
Hersch M, Raveh D, Izbicki G: Effect of Intravenous Propacetamol on Blood Pressure in Febrile Critically Ill Patients, 1205
Hester EK: see Hornsby LB, et al, 536
Hewlett D Jr: see Fang AF, et al, 42
Hidayat L: see Beringer PM, et al, 883
Higginson RT: see Pecora Fulco P, et al, 945
Hilleman D: see Maciejewski S, et al, 570
Hill-Zabala C: see ACCP, et al, 229e, 1421
Hobbs RA: see Bream-Rouwenhorst HR, et al, 1401
Hoetelmans RMW: see Schöller-Gyüre M, et al, 1215
Hoffman JM: see Perez A, et al, 285e
Hornsby LB, Hester EK, Donaldson AR: Potential Interaction Between Warfarin and High Dietary Protein Intake, 536
Horvath K: see Studdiford J, et al, 1194
Hsiong C-H: see Lin C-J, et al, 35
Hu OY-P: see Lin C-J, et al, 35
Hung C-C: see Lin C-J, et al, 35
Hunt J: The Future of Advanced Pharmacy Practice: Wildcats versus Zeros, 277e
Hutchison RW: see Herndon CM, et al, 788
Hylek EM: see Bussey HI, et al, 141
Hylek EM: see Clark NP, et al, 960

- I -

Iacovelli LM: see Arbuckle RB, et al, 1S
Ibe AI: see Makhzoumi ZH, et al, 1198
Innocenti F: see Perera MA, et al, 755
Irons BK: see Edwards KL, et al, 506
Iseman MD: see Schwiesow JN, et al, 1076
Iulio J: see Csajka C, et al, 215e
Izbicki G: see Hersch M, et al, 1205

- J -

Jacobsen J: see Gasse C, et al, 27
Jakubowski JA: see Farid NA, et al, 1483
James LP: see O'Brien CE, et al, 1059
Jarkowski A III, Sweeney RP: Nilotinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia, 1374
Jarzyna DL: see Patanwala AE, et al, 1453
Jean GW, Shah SR: Epidermal Growth Factor Receptor Monoclonal Antibodies for the Treatment of Metastatic Colorectal Cancer, 742
Jennings HR: see Suffoletta TJ, et al, 1133
Jick H: see Kaye JA, et al, 951
Jick SS, Li L: Antidepressant Drug Use and Risk of Venous Thromboembolism, 144
Johnsen SP: see Gasse C, et al, 27
Johnson C: see Pakyz A, et al, 906
Johnson EP: see Arria AM, et al, 156
Johnson JA: Warfarin: An Old Drug but Still Interesting, 1081
Johnson M: see Mohr J, et al, 614
Johnson PE: see Arbuckle RB, et al, 1S
Jorgenson JA: see Arbuckle RB, et al, 1S

- K -

Kaakeh Y, Stumpf JL: Treatment of Selective Mutism: Focus on Selective Serotonin Reuptake Inhibitors, 214
Kakuda TN: see Schöller-Gyüre M, et al, 1215
Kale-Pradhan PB: see Wilhelm SM, et al, 496
Kane-Gill S, Reddy P, Gupta SR, Bakst AW: Guidelines

for Pharmacoeconomic and Outcomes Research Fellowship Training Programs, 269e, 1552
Kaneria RM: see Picard LS, et al, 530
Kasirajan V: see Crouch MA, et al, 1413
Katlaps GJ: see Crouch MA, et al, 1413
Kaye JA, Jick H: Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors, 951
Kays MB: see Cheatham SC, et al, 691
Kearns GL: see Kennedy MJ, et al, 1495
Keck PE Jr: see Picard LS, et al, 530
Kelly F: see Raissy HH, et al, 287
Kelly HW: see Raissy HH, et al, 287
Kennedy MJ, Loehle JA, Griffin AR, Doll MA, Kearns GL, Sullivan JE, Hein DW: Association of the Histamine *N*-Methyltransferase C314T (Thr105Ile) Polymorphism with Atopic Dermatitis in Caucasian Children, 1495
Kenyon K: see Seto AC, et al, 1098
Kernan W: see Leung S, et al, 3e
Kessels A: see Nappi J, et al, 819
Khamaisi M, Leitersdorf E: Severe Hypoglycemia from Clarithromycin-Repaglinide Drug Interaction, 682
Khanmoradi K: see Tuteja S, et al, 1188
Kincaid EH: see Reichert MG, et al, 151
King AE, Umland EM: Osteonecrosis of the Jaw in Patients Receiving Intravenous or Oral Bisphosphonates, 667
Kingery JR: see Tisdale JE, et al, 1461
Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ: Increased Risk of Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease in Men Receiving Androgen Deprivation Therapy for Prostate Cancer, 1511
Kirton OC: see Sobieraj DM, et al, 1537
Kiser TH, Burch JC, Klem PM, Hassell KL: Safety, Efficacy, and Dosing Requirements of Bivalirudin in Patients with Heparin-Induced Thrombocytopenia, 1115
Kissack JC, Bishop J, Roper AM: Ethylglucuronide as a Biomarker for Ethanol Detection, 769
Klee JA: see Lawrence KR, et al, 1019
Klem PM: see Kiser TH, et al, 1115
Klepser ME: see ACCP, et al, 229e, 1421
Klibanov OM: see Correll T, et al, 90
Kloth DD: see Arbuckle RB, et al, 1S
Knoell D: see Figg WD, et al, 821
Knudsen JF, Sokol GH: Potential Glucosamine-Warfarin Interaction Resulting in Increased International Normalized Ratio: Case Report and Review of the Literature and MedWatch Database, 540
Koda-Kimble MA: see Figg WD, et al, 821
Kon ND: see Reichert MG, et al, 151
Konkoy CS: see Farid NA, et al, 1483
Kovacs RJ: see Tisdale JE, et al, 1461
Kriengkauykiat J: see Beringer PM, et al, 883
Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA: Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome, 1223
Kristeller JL, Roslund BP, Stahl RF: Benefits and Risks of Aprotinin Use During Cardiac Surgery, 112
Kroboth P: see Figg WD, et al, 821
Kubota M: see Cohen CJ, et al, 314
Kuehl TJ: see Coffee AL, et al, 576
Kuhl DA: see Dickerson RN, et al, 308
Kurtzeborn CM: see Brielmaier BD, et al, 64
Kuti JL: see Laohavaleeson S, et al, 1471
Kuti JL: see Nicasio AM, et al, 235

- L -

LaBadie RR: see Fang AF, et al, 42
Laban KM: see Garwood CL, et al, 20
LaFollette JA: see Lutomski DM, et al, 1348
Lam SW, Bauer SR, Cha SS, Oyen LJ: Lack of an Effect of Body Mass on the Hemodynamic Response to Arginine Vasopressin During Septic Shock, 591
Lamb K: see Studdiford J, et al, 1194
Lancaster CT: see Cao Y-J, et al, 863
Lancaster J, Sylvia LM, Schainker ES: Nonbloody, Red Stools from Coadministration of Cefdinir and Iron-Supplemented Infant Formulas, 678
Lancaster JW, Lawrence KR, Fong JJ, Doron SI, Garpestad E, Nasraway SA, Devlin JW: Impact of an Institution-Specific Hospital-Acquired Pneumonia Protocol on the Appropriateness of Antibiotic Therapy and Patient Outcomes, 852
Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL: Cost-Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections, 1471
LaPlante KL, Mersfelder TL, Ward KE, Quilliam BJ: Prevalence of and Risk Factors for Dysglycemia in Patients Receiving Gatifloxacin and Levofloxacin in an Outpatient Setting, 82
Lawrence KR, Klee JA: Rifaximin for the Treatment of Hepatic Encephalopathy, 1019
Lawrence KR: see Golik MV, et al, 1125
Lawrence KR: see Lancaster JW, et al, 852
Lee JH: see Makhzoumi ZH, et al, 1198
Lee K-V: see Walton SM, et al, 1443
Lee MR: see Stevens DL, et al, 403
Leemans R: see Schöller-Gyüre M, et al, 1215
Lehr VT: see Abdulhamid I, et al, 939
Leitersdorf E: see Khamaisi M, et al, 682
Leloux MR: see Weber CA, et al, 1104
Lennox JL: see Ofotokun I, et al, 74
Leonard SN, Rybak MJ: Telavancin: An Antimicrobial with a Multifunctional Mechanism of Action for the Treatment of Serious Gram-Positive Infections, 458
Lesko LJ: see Frueh FW, et al, 992
Leung S, Poulakos MN, Kernan W: Is the Drug Interaction Actual between Posaconazole and Cyclosporine?, 3e
Leung S, Poulakos MN, Ramirez-Ruiz L: Comparing Unbound Plasma Posaconazole Levels to Fungal Minimal Inhibitory Concentrations (MICs) in Allogeneic Hematopoietic Stem Cell Transplant

(HSCT) Recipients with Graft-Versus-Host Disease (GVHD), 83e
Levi DM: see Tuteja S, et al, 1188
Lewandowski MJ, Chapman SA: Ondansetron-Induced Aminotransferase Level Elevation: Case Report and Review of the Literature, 1542
Lewis JS II: see Mohr J, et al, 614
Li L: see Jick SS, et al, 144
Li YG: see Farid NA, et al, 1483
Lim ML: see Cohen CJ, et al, 314
Limdi NA, Veenstra DL: Warfarin Pharmacogenetics, 1084
Lin C-J, Yen M-F, Hu OY-P, Lin M-S, Hsiong C-H, Hung C-C, Liou H-H: Association of Galactose Single-Point Test Levels and Phenytoin Metabolic Polymorphisms with Gingival Hyperplasia in Patients Receiving Long-Term Phenytoin Therapy, 35
Lin M-S: see Lin C-J, et al, 35
Lindauer K: see ACCP, et al, 7e, 285
Lindsay S: see Picard LS, et al, 530
Liou H-H: see Lin C-J, et al, 35
Liu S: see Beringer PM, et al, 883
Liu-DeRyke X, Rhoney DH: Hemostatic Therapy for the Treatment of Intracranial Hemorrhage, 485
Liu-DeRyke X: see Forsyth LL, et al, 469
Lloyd E: see Metz DC, et al, 301
Loehle JA: see Kennedy MJ, et al, 1495
Lou Y: see Cao Y-J, et al, 863
Louie S: see Beringer PM, et al, 883
Lucarelli CD: see Arbuckle RB, et al, 1S
Lutomski DM, LaFollette JA, Biaglow MA, Haglund LA: Antibiotic Allergies in the Medical Record: Effect on Drug Selection and Assessment of Validity, 1348

- M -

Ma Q: see ACCP, et al, 93e, 1203
Maciejewski S, Hilleman D: Effectiveness of a Fenofibrate 145-mg Nanoparticle Tablet Formulation Compared with the Standard 160-mg Tablet in Patients with Coronary Heart Disease and Dyslipidemia, 570
MacLaughlin EJ: see Boyce EG, et al, 245e
MacLaughlin EJ: see Gallegos PJ, et al, 343
Maclayton DO: see Nguyen ST, et al, 323
Majerus T: see ACCP, et al, 229e, 1421
Makhzoumi ZH, McLean LP, Lee JH, Ibe AI: Diabetic Ketoacidosis Associated with Aripiprazole, 1198
Malesker MA: Optimizing Antidiabetic Treatment Options for Patients with Type 2 Diabetes Mellitus and Cardiovascular Comorbidities, 193
Marino J, Caballero J: Paliperidone Extended-Release for the Treatment of Schizophrenia, 1283
Marrs JC, Saseen JJ: Debating the Clinical Benefits of Ranolazine and its Role in Therapy, 85e
Marrs JC, Saseen JJ: Dyslipidemia Control in Indigent Patients Receiving Medication Assistance Compared with Insured Patients, 562
Martinez E: see Cao Y-J, et al, 863
Martinho M: see Krishna G, et al, 1223
Mascitelli L, Pezzetta F, Goldstein MR: Statin Therapy and Intracerebral Hemorrhage, 35e
Massicotte A: Contrast Medium–Induced Nephropathy: Strategies for Prevention, 1140
Matschke K: see Zimmerman JJ, et al, 895
Matzke GR: see ACCP, et al, 229e, 1421
Matzke GR: see Maynor LM, et al, 977
Maynor LM, Carl DE, Matzke GR, Gehr TWB, Farthing C, Farthing D, Brophy DF: An In Vivo–In Vitro Study of Cefepime and Cefazolin Dialytic Clearance During High-Flux Hemodialysis, 977
McCabe S: see Cao Y-J, et al, 863
McClune B: see Przepiorka D, et al, 58
McCune JS: see Eberly AL, et al, 1502
McDonald CJ: see Hansen RA, et al, 1325
McGivney MS: see ACCP, et al, 7e, 285
McKinnon PS: see Brielmaier BD, et al, 64
McLean LP: see Makhzoumi ZH, et al, 1198
McLeay PD: see Daly MW, et al, 1408
McLeod H: see Figg WD, et al, 821
Meek PD: see Perez A, et al, 285e
Meilichov I: see Fuchs T, et al, 14
Meltzer D: see Walton SM, et al, 1443
Mersfelder TL: see LaPlante KL, et al, 82
Mertens MK: see Grice GR, et al, 397
Metz DC, Devlin JW, Vakily M, Atkinson S, Lloyd E: Greater Immediate Gastric Acid Suppression with Lansoprazole 30 mg Administered as a 2-Minute Intravenous Bolus Injection versus a 30-Minute Infusion, 301
Milchak JL, Carter BL, Ardery G, Dawson JD, Harmston M, Franciscus CL: Physician Adherence to Blood Pressure Guidelines and Its Effect on Seniors, 843
Miller AE, Hansen LB, Saseen JJ: Switching Statin Therapy Using a Pharmacist-Managed Therapeutic Conversion Program versus Usual Care Conversion Among Indigent Patients, 553
Miller HB: see Onofrei MD, et al, 522
Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP: Comparison of Intranasal Administration of Haloperidol with Intravenous and Intramuscular Administration: A Pilot Pharmacokinetic Study, 875
Miller K: see Figg WD, et al, 821
Miller LJ: Prazosin for the Treatment of Posttraumatic Stress Disorder Sleep Disturbances, 656
Miller MD: see Patanwala AE, et al, 1453
Miller WA: see ACCP, et al, 806
Minard G: see Dickerson RN, et al, 308
Mitrzyk BM: Treatment of Extensively Drug-Resistant Tuberculosis and Role of the Pharmacist, 1243
Mohammad RA: see Btaiche IF, et al, 600
Mohr J, Johnson M, Cooper T, Lewis JS II, Ostrosky-Zeichner L: Current Options in Antifungal Pharmacotherapy, 614
Montoya ID: see Corbett SM, et al, 250
Moore FA: see Corbett SM, et al, 250
Mortensen PB: see Gasse C, et al, 27

Movsesian M: see Van Tassell BW, et al, 1523
Mueller BA: see Btaiche IF, et al, 600
Mueller EW, Rockey ML, Rashkin MC: Sunitinib-Related Fulminant Hepatic Failure: Case Report and Review of the Literature, 1066
Muller RJ: see Arbuckle RB, et al, 1S
Mummaneni P: see Frueh FW, et al, 992
Munger MA, Gardner SF, Ateshkadi A, Rabetoy GM, Barri YM, Stoddard GJ, Cheung AK: Misoprostol Effects on Diclofenac-Induced Cardiorenal Changes in Salt-Sensitive Patients with Hypertension: The MEDIC Study, 834
Munger MA: see Van Tassell BW, et al, 1523
Murphy CE, Stevens AM, Ferrentino N, Crookes BA, Hebert JC, Freiburg CB, Rebuck JA: Frequency of Inappropriate Continuation of Acid Suppressive Therapy After Discharge in Patients Who Began Therapy in the Surgical Intensive Care Unit, 968
Murray MD: see Hansen RA, et al, 1325
Muthiah MP: see Usery JB, et al, 1183

- N -

Nafziger AN: see Hameed MS, et al, 707
Nappi J, Haase K, Kessels A, Fink J: What is a Pharmacotherapy Residency? Benefits of a 24-Month Program, 819
Nappi JM: see Choy CK, et al, 170
Nasraway SA: see Lancaster JW, et al, 852
Nazeri E: see ACCP, et al, 93e, 1203
Neff WJ: see Pick AM, et al, 406
Neft RA: see Vaisleib II, et al, 1211
Neft RA: see Vaisleib II, et al, 393
Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ: Lipid-Lowering Efficacy and Safety After Switching to Atazanavir-Ritonavir–Based Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus, 323
Nguyen ST: see Rahman AP, et al, 913
Nicasio AM, Kuti JL, Nicolau DP: The Current State of Multidrug-Resistant Gram-Negative Bacilli in North America: Insights from the Society of Infectious Diseases Pharmacists, 235
Nicolau DP: see Laohavaleeson S, et al, 1471
Nicolau DP: see Nicasio AM, et al, 235
Nørgaard M: see Gasse C, et al, 27
Norgard NB, Stark JE: Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and β-Blockers, 920
Nystrom KK: see Pick AM, et al, 406

- O -

O'Brien CE, Harik N, James LP, Seib PM, Stowe CD: Cesium-Induced QT-Interval Prolongation in an Adolescent, 1059
O'Bryant CL, Flaig TW, Utz KJ: Bicalutamide-Associated Fulminant Hepatotoxicity, 1071
O'Grady KE: see Arria AM, et al, 156
O'Rourke TJ: see Kintzel PE, et al, 1511
Ofotokun I, Acosta EP, Lennox JL, Pan Y, Easley KA: Pharmacokinetics of an Indinavir-Ritonavir-Fosamprenavir Regimen in Patients with Human Immunodeficiency Virus, 74
Oh JJ: see Suffoletta TJ, et al, 1133
Okita R: see Figg WD, et al, 821
Olson KL: see Gaffney SM, et al, 1041
Onofrei MD, Butler KL, Fuke DC, Miller HB: Safety of Statin Therapy in Patients with Preexisting Liver Disease, 522
Orlando PL: see ACCP, et al, 1548
Orlando PL: see ACCP, et al, 219e, 1547
Ostrosky-Zeichner L: see Mohr J, et al, 614
Oteri A, Catania MA, Travaglini R, Russo A, Giustini SE, Caputi AP, Polimeni G: Gynecomastia Possibly Induced by Rosuvastatin, 549
Ott C: see ACCP, et al, 93e, 1203
Ottum SA: see Touchette DR, et al, 584
Overholser BR, Zheng X, Tisdale JE: Catecholaminergic Effects on Ventricular Repolarization During Inhibition of the Rapid Component of the Delayed Rectifier Potassium Current in a Perfused Heart Model, 1315
Overholser BR: see Tisdale JE, et al, 1461
Owen P, Garner J, Hergott L, Page RL II: Clopidogrel Desensitization: Case Report and Review of Published Protocols, 259
Oyen LJ: see Lam SW, et al, 591

- P -

Padua Y: see Stevens DL, et al, 403
Page RL II, Ruscin JM, Bainbridge JL, Brieke AA: Restless Legs Syndrome Induced by Escitalopram: Case Report and Review of the Literature, 271
Page RL II: see Owen P, et al, 259
Pai VB, Sakadjian A, Puthoff TD: Ibuprofen Lysine for the Prevention and Treatment of Patent Ductus Arteriosus, 1162
Pakyz A, Powell JP, Harpe SE, Johnson C, Edmond M, Polk RE: Diversity of Antimicrobial Use and Resistance in 42 Hospitals in the United States, 906
Pan Y: see Ofotokun I, et al, 74
Parker D Jr: see Forsyth LL, et al, 469
Partovi N: see Bring P, et al, 331
Patanwala AE, Jarzyna DL, Miller MD, Erstad BL: Comparison of Opioid Requirements and Analgesic Response in Opioid-Tolerant versus Opioid-Naïve Patients After Total Knee Arthroplasty, 1453
Patel NC: see Picard LS, et al, 530
Payne CD: see Farid NA, et al, 1483
Payne KD: see Nguyen ST, et al, 323
Payne KD: see Rahman AP, et al, 913
Pecora Fulco P, Zingone MM, Higginson RT: Possible Antiretroviral Therapy–Warfarin Drug Interaction, 945
Pedersen L: see Gasse C, et al, 27
Peeters M: see Schöller-Gyüre M, et al, 1215
Peloquin CA: see Schwiesow JN, et al, 1076
Perera MA, Innocenti F, Ratain MJ: Pharmacogenetic

Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphisms: Are We There Yet?, 755
Perez A, Doloresco F, Hoffman JM, Patrick D, Meek PD, Touchette DR, Vermeulen LC, Schumock GT: Economic Evaluations of Clinical Pharmacy Services: 2001–2005, 285e
Pezzetta F: see Mascitelli L, et al, 35e
Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE Jr: Atypical Neuroleptic Malignant Syndrome: Diagnostic Controversies and Considerations, 530
Pick AM, Neff WJ, Nystrom KK: Temozolomide-Induced Desquamative Skin Rash in a Patient with Metastatic Melanoma, 406
Pickard AS, Becker RC, Schumock GT, Frye CB: Clopidogrel-Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting, 376
Pieper J: see Figg WD, et al, 821
Ploch PJ: see Whitman CB, et al, 131
Poe KL: see Suffoletta TJ, et al, 1133
Polimeni G: see Oteri A, et al, 549
Polk RE: see Pakyz A, et al, 906
Poon IO: Effects of Antihypertensive Drug Treatment on the Risk of Dementia and Cognitive Impairment, 366
Poulakos MN: see Leung S, et al, 3e
Poulakos MN: see Leung S, et al, 83e
Powell JP: see Pakyz A, et al, 906
Pozniak AL: see Schöller-Gyüre M, et al, 1215
Preusch P: see Figg WD, et al, 821
Przepiorka D, Buadi FK, McClune B: Oral Voriconazole for Empiric Antifungal Treatment in Patients with Uncomplicated Febrile Neutropenia, 58
Puthoff TD: see Pai VB, et al, 1162
Pyrsopoulos NT: see Tuteja S, et al, 1188

- Q -

Quilliam BJ: see LaPlante KL, et al, 82

- R -

Rabetoy GM: see Munger MA, et al, 834
Radebaugh C: see Cao Y-J, et al, 863
Radwanski P: see Van Tassell BW, et al, 1523
Raebel MA: see ACCP, et al, 229e, 1421
Raehl CL: see Bond CA, et al, 1
Raghavendran K: see Whitman CB, et al, 131
Ragucci DP: see ACCP, et al, 806
Ragucci KR: see ACCP, et al, 7e, 285
Rahman AP, Eaton SA, Nguyen ST, Bain AM, Payne KD, Bedimo R, Busti AJ: Safety and Efficacy of Simvastatin for the Treatment of Dyslipidemia in Human Immunodeficiency Virus–Infected Patients Receiving Efavirenz-Based Highly Active Antiretroviral Therapy, 913
Rahman AP: see Bain AM, et al, 932
Rahman AP: see Nguyen ST, et al, 323
Raible DG: see Zimmerman JJ, et al, 895
Raissy HH, Harkins M, Kelly F, Kelly HW: Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children, 287
Ramirez MA, Borja NL: Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy, 646
Ramirez-Ruiz L: see Leung S, et al, 83e
Rao PA: see Beringer PM, et al, 883
Rashkin MC: see Mueller EW, et al, 1066
Ratain MJ: see Perera MA, et al, 755
Raveh D: see Hersch M, et al, 1205
Rebuck JA: see Murphy CE, et al, 968
Reddy P: see Kane-Gill S, et al, 269e, 1552
Reed M: see Figg WD, et al, 821
Reeves DJ, Bestul DJ: Evaluation of a Single Fixed Dose of Rasburicase 7.5 mg for the Treatment of Hyperuricemia in Adults with Cancer, 685
Reichert MG, Robinson AH, Travis JA, Hammon JW Jr, Kon ND, Kincaid EH: Effects of a Waiting Period After Clopidogrel Treatment Before Performing Coronary Artery Bypass Grafting, 151
Resman-Targoff BH: see ACCP, et al, 1548
Resman-Targoff BH: see ACCP, et al, 219e, 1547
Rhoney DH: see Forsyth LL, et al, 469
Rhoney DH: see Liu-DeRyke X, et al, 485
Riker RR: see Yahwak JA, et al, 984
Ripley TL: see Gaffney SM, et al, 1041
Ritchie DJ: see Brielmaier BD, et al, 64
Robinette B: see Gaffney SM, et al, 1041
Robinson AH: see Reichert MG, et al, 151
Rockey ML: see Mueller EW, et al, 1066
Rodgers JE: see Choy CK, et al, 170
Rodriguez-Barradas MC: see Nguyen ST, et al, 323
Rogers DP: see Goldsmith C-AW, et al, 730
Romanelli F, Whisman T, Fink JL III: Issues Surrounding Lethal Injection as a Means of Capital Punishment, 1429
Roper AM: see Kissack JC, et al, 769
Roslund BP: see Kristeller JL, et al, 112
Rospond RM: see Boyce EG, et al, 245e
Rotger M: see Csajka C, et al, 215e
Rudy AC: see Miller JL, et al, 875
Ruscin JM: see Page RL II, et al, 271
Russo A: see Oteri A, et al, 549
Rutherford WS: see Bain AM, et al, 932
Rybak MJ: see Leonard SN, et al, 458

- S -

Saadeh CE, Srkalovic G: *Mycobacterium avium* Complex Infection After Alemtuzumab Therapy for Chronic Lymphocytic Leukemia, 281
Saitoh A: see Torno MS, et al, 782
Sakadjian A: see Pai VB, et al, 1162
Salazar DE: see Farid NA, et al, 1483
Saseen JJ: see Marrs JC, et al, 562
Saseen JJ: see Marrs JC, et al, 85e
Saseen JJ: see Miller AE, et al, 553
Saseen JJ: see Vande Griend JP, et al, 1233
Schainker ES: see Lancaster J, et al, 678
Schiff ER: see Tuteja S, et al, 1188
Schneider JK, Gardner DK, Cordero L: Use of

Recombinant Human Erythropoietin and Risk of Severe Retinopathy in Extremely Low-Birth-Weight Infants, 1335
Schneider S: see Cohen CJ, et al, 314
Schöller-Gyüre M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, Vyncke V, Peeters M, Vandermeulen K, Hoetelmans RMW: Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine, 1215
Schroeder WS: see Whitman CB, et al, 131
Schultz LM: see Kintzel PE, et al, 1511
Schumock GT: see Perez A, et al, 285e
Schumock GT: see Pickard AS, et al, 376
Schumock GT: see Walton SM, et al, 1443
Schwiesow JN, Iseman MD, Peloquin CA: Concomitant Use of Voriconazole and Rifabutin in a Patient with Multiple Infections, 1076
See S, Ginzburg R: Skeletal Muscle Relaxants, 207
Segal AR: see Boyce EG, et al, 245e
Seib PM: see O'Brien CE, et al, 1059
Self TH: see Usery JB, et al, 1183
Selvaggi G: see Tuteja S, et al, 1188
Seto AC, Kenyon K, Wittkowsky AK: Discrepancies in Identification of Major Bleeding Events in Patients Taking Warfarin, 1098
Shaefer MS: see Cohen CJ, et al, 314
Shah SR: see Jean GW, et al, 742
Shapiro B: see Beringer PM, et al, 883
Shrader SP, Dickerson LM: Extended- and Continuous-Cycle Oral Contraceptives, 1033
Small DS: see Farid NA, et al, 1483
Smith DW: see Cheatham SC, et al, 691
Smith JP: Treatment Options for Patients with Hepatitis C: Role of Pharmacists in Optimizing Treatment Response and Managing Adverse Events, 1151
Smith LS: see ACCP, et al, 1548
Smith LS: see ACCP, et al, 219e, 1547
Smith PF: see Cao Y-J, et al, 863
Smith WE: see ACCP, et al, 806
Smythe MA: see ACCP, et al, 1548
Smythe MA: see ACCP, et al, 219e, 1547
Sobieraj DM, Wang F, Kirton OC: Warfarin Resistance After Total Gastrectomy and Roux-en-Y Esophagojejunostomy, 1537
Sokol GH: see Knudsen JF, et al, 540
Sørensen HT: see Gasse C, et al, 27
Sowinski KM: see Cheatham SC, et al, 691
Sowinski KM: see Tisdale JE, et al, 1461
Speedie M: see Figg WD, et al, 821
Spencer AP: see ACCP, et al, 806
Spencer AP: see Gaffney SM, et al, 1041
Speth JL: see Zimmerman JJ, et al, 895
Spinler SA: see Baetz BE, et al, 1354
Spriet I: see von Winckelmann SL, et al, 1391
Srkalovic G: see Saadeh CE, et al, 281
Stacy ZA: see Herndon CM, et al, 788
Stafford RS: see Walton SM, et al, 1443
Stahl RF: see Kristeller JL, et al, 112
Stark JE: see Norgard NB, et al, 920
Stephens D: see Suffoletta TJ, et al, 1133
Stevens AM: see Murphy CE, et al, 968
Stevens DL, Lee MR, Padua Y: Olanzapine-Associated Neuroleptic Malignant Syndrome in a Patient Receiving Concomitant Rivastigmine Therapy, 403
Stoddard GJ: see Munger MA, et al, 834
Stonehouse A: see Studdiford J, et al, 1194
Stowe CD: see O'Brien CE, et al, 1059
Strawn JR: see Picard LS, et al, 530
Stubbings TW: see Delate T, et al, 444
Studdiford J, Lamb K, Horvath K, Altshuler M, Stonehouse A: Development of Unilateral Cervical and Supraclavicular Lymphadenopathy After Human Papilloma Virus Vaccination, 1194
Stumpf JL: see Kaakeh Y, et al, 214
Subak-Sharpe S: see Yahwak JA, et al, 984
Suffoletta TJ, Jennings HR, Oh JJ, Stephens D, Poe KL: Continuous versus Intermittent Infusion of Prophylactic Cefoxitin After Colorectal Surgery: A Pilot Study, 1133
Sulak PJ: see Coffee AL, et al, 576
Sullivan JE: see Kennedy MJ, et al, 1495
Summers KM: see Gaffney SM, et al, 1041
Surowiec D, DePestel DD, Carver PL: Concurrent Administration of Sirolimus and Voriconazole: A Pilot Study Assessing Safety and Approaches to Appropriate Management, 719
Sutherland-Phillips DH: see Cohen CJ, et al, 314
Sweeney RP: see Jarkowski A III, et al, 1374
Sylvia LM: see Lancaster J, et al, 678
Synold T: see Beringer PM, et al, 883

- T -

Taylor AT: see ACCP, et al, 7e, 285
Taylor MB, Gutierrez MJ: Absorption, Bioavailability, and Partner Transfer of Estradiol from a Topical Emulsion, 712
Taylor P: see Figg WD, et al, 821
Telenti A: see Csajka C, et al, 215e
Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ: Pharmacokinetics of Ibutilide in Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction, 1461
Tisdale JE: see Overholser BR, et al, 1315
Torno MS, Witt MD, Saitoh A, Fletcher CV: Successful Use of Reduced-Dose Efavirenz in a Patient with Human Immunodeficiency Virus Infection: Case Report and Review of the Literature, 782
Touchette DR, Bearden DT, Ottum SA: Research Publication by Pharmacist Authors in Major Medical Journals: Changes over a 10-Year Interval, 584
Touchette DR: see Perez A, et al, 285e
Tracy TS: see Figg WD, et al, 821
Trapp M: see Clark NP, et al, 960
Travaglini R: see Oteri A, et al, 549
Travis JA: see Reichert MG, et al, 151
Tu W: see Hansen RA, et al, 1325

Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM, Selvaggi G, Weisbaum G, Tzakis AG, Schiff ER: Simvastatin-Ezetimibe–Induced Hepatic Failure Necessitating Liver Transplantation, 1188
Tzakis AG: see Tuteja S, et al, 1188

- U -

Ujhelyi MR: Scared to Death, 1311
Umland EM: see King AE, et al, 667
Usery JB, Self TH, Muthiah MP, Finch CK: Potential Role of Leukotriene Modifiers in the Treatment of Chronic Obstructive Pulmonary Disease, 1183
Utz KJ: see O'Bryant CL, et al, 1071

- V -

Vaida SJ: see Young SK, et al, 1531
Vaisleib II, Neft RA: Overnight Transition from Carbamazepine to Oxcarbazepine in Children and Adolescents, 1211
Vaisleib II, Neft RA: Rapid Dosage Titration of Levetiracetam in Children, 393
Vakily M: see Metz DC, et al, 301
Valley AW: see ACCP, et al, 806
Van Tassell BW, Radwanski P, Movsesian M, Munger MA: Combination Therapy with β-Adrenergic Receptor Antagonists and Phosphodiesterase Inhibitors for Chronic Heart Failure, 1523
Vande Griend JP, Saseen JJ: Combination Antiplatelet Agents for Secondary Prevention of Ischemic Stroke, 1233
Vandermeulen K: see Schöller-Gyüre M, et al, 1215
Varcak EA: see Wilhelm SM, et al, 496
Veenstra DL: see Limdi NA, et al, 1084
Verbrugge RR: see Frueh FW, et al, 992
Vermeulen LC: see Doloresco F, et al, 4e
Vermeulen LC: see Perez A, et al, 285e
Vincent KB: see Arria AM, et al, 156
Vivian E: see ACCP, et al, 229e, 1421
Vivian EM: see Wubben DP, et al, 421
von Winckelmann SL, Spriet I, Willems L: Therapeutic Drug Monitoring of Phenytoin in Critically Ill Patients, 1391
Vyncke V: see Schöller-Gyüre M, et al, 1215

- W -

Wack MF: see Cheatham SC, et al, 691
Walker MB: see Bussey HI, et al, 141
Walton SM, Schumock GT, Lee K-V, Alexander GC, Meltzer D, Stafford RS: Prioritizing Future Research on Off-Label Prescribing: Results of a Quantitative Evaluation, 1443
Wang F: see Sobieraj DM, et al, 1537
Wang J: see Hansen RA, et al, 1325
Ward KE: see LaPlante KL, et al, 82
Wargo KA: Clinical Judgment: To Renal Dose Adjust Antimicrobials or Not, 281e
Weber CA, Leloux MR, Carter BL, Farris KB, Xu Y: Reduction in Adverse Symptoms as Blood Pressure Becomes Controlled, 1104
Weber CA: see Fravel MA, et al, 1341
Weimert N: see ACCP, et al, 229e, 1421
Weisbaum G: see Tuteja S, et al, 1188
Wells BG: see Boyce EG, et al, 245e
Wermeling D: see ACCP, et al, 93e, 1203
Wermeling DP: see Miller JL, et al, 875
Whisman T: see Romanelli F, et al, 1429
White EA: see Bain AM, et al, 932
Whitman CB, Schroeder WS, Ploch PJ, Raghavendran K: Efficacy of Aminophylline for Treatment of Recurrent Symptomatic Bradycardia After Spinal Cord Injury, 131
Widmer N: see Csajka C, et al, 215e
Wiggins B: see ACCP, et al, 229e, 1421
Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB: Effectiveness of Probiotics in the Treatment of Irritable Bowel Syndrome, 496
Willems L: see von Winckelmann SL, et al, 1391
Williams VC: see Cohen CJ, et al, 314
Willson DF: see Buck ML, et al, 51
Winstead PS: see Ball AM, et al, 1383
Winters KJ: see Farid NA, et al, 1483
Winterstein AG: see Gerhard T, et al, 1e
Wire MB: see Cao Y-J, et al, 863
Wise TL: see Abdulhamid I, et al, 939
Wish ED: see Arria AM, et al, 156
Witt DM: see Clark NP, et al, 960
Witt MD: see Torno MS, et al, 782
Wittkowsky AK: see Bussey HI, et al, 141
Wittkowsky AK: see Seto AC, et al, 1098
Wolowich WR: see Tuteja S, et al, 1188
Woodfall B: see Schöller-Gyüre M, et al, 1215
Wroblewski HA: see Tisdale JE, et al, 1461
Wubben DP, Vivian EM: Effects of Pharmacist Outpatient Interventions on Adults with Diabetes Mellitus: A Systematic Review, 421

- X, Y -

Xu Y: see Weber CA, et al, 1104
Xuan F: see Krishna G, et al, 1223
Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S: Determination of a Lorazepam Dose Threshold for Using the Osmol Gap to Monitor for Propylene Glycol Toxicity, 984
Yen M-F: see Lin C-J, et al, 35
Yoshida EM: see Bring P, et al, 331
Young SK, Al-Mondhiry HA, Vaida SJ, Ambrose A, Botti JJ: Successful Use of Argatroban During the Third Trimester of Pregnancy: Case Report and Review of the Literature, 1531

- Z -

Zaffanello M, Franchini M, Fanos V: New Therapeutic Strategies with Combined Renin-Angiotensin System Inhibitors for Pediatric Nephropathy, 125
Zafirau WJ: see Fosnight SM, et al, 225
Zellmer WA: Pharmacy Vision and Leadership: Revisiting the Fundamentals, 1437
Zhang X: see Beringer PM, et al, 883
Zheng X: see Overholser BR, et al, 1315

Zimmerman JJ, Raible DG, Harper DM, Matschke K, Speth JL: Evaluation of a Potential Tigecycline-Warfarin Drug Interaction, 895

Zineh I: see Gerhard T, et al, 1e
Zingone MM: see Pecora Fulco P, et al, 945
Zipes DP: see Tisdale JE, et al, 1461

Index to Volume 28

Subject Index

- A -

Abacavir-lamivudine combination, short-term safety and tolerability of a once-daily fixed-dose, versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study, 314

Acid suppressive therapy, frequency of inappropriate continuation of, after discharge in patients who began therapy in the surgical intensive care unit, 968

Adherence rates, comparison of drug, among patients with seven different medical conditions, 437

Albuterol versus montelukast, pretreatment with, for exercise-induced bronchospasm in children, 287

Alemtuzumab therapy for chronic lymphocytic leukemia, *Mycobacterium avium* complex infection after, 281

Allergies, antibiotic, in the medical record: effect on drug selection and assessment of validity, 1348

Amino acid requirements in critically ill patients with acute kidney injury treated with continuous renal replacement therapy, 600

Aminophylline, efficacy of, for treatment of recurrent symptomatic bradycardia after spinal cord injury, 131

Androgen deprivation therapy for prostate cancer, increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving, 1511

Anemia of critical illness, 1267

Anidulafungin, early clinical experience with, at a large tertiary care medical center, 64

Antibiotic allergies in the medical record: effect on drug selection and assessment of validity, 1348

Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia, 356

Anticoagulation clinic, quality of anticoagulation care in patients discharged from a pharmacist-managed after stabilization of warfarin therapy, 20

Antidepressant drug use and risk of venous thromboembolism, 144

Anti–epidermal growth factor receptor monoclonal antibodies and anti–vascular endothelial growth factor with chemotherapy, systemic therapy for advanced or metastatic colorectal cancer: national comprehensive cancer network guidelines for combining, 18S

Anti–epidermal growth factor receptor monoclonal antibodies, clinical use of, in metastatic colorectal cancer, 31S

Antifungal pharmacotherapy, current options in, 614

Antihypertensive drug treatment, effects of, on the risk of dementia and cognitive impairment, 366

Antimicrobial drugs, comparison of dosing recommendations for, based on two methods for assessing kidney function: Cockcroft-Gault and modification of diet in renal disease, 1125

Antimicrobial use and resistance, diversity of, in 42 hospitals in the United States, 906

Antiplatelet agents, combination, for secondary prevention of ischemic stroke, 1233

Antiretroviral therapy–warfarin drug interaction, possible, 945

Antiretroviral-associated dyslipidemia, a multimodal, evidence-based approach to achieve lipid targets in the treatment of, case report and review of the literature, 932

Anti–vascular endothelial growth factor and anti–epidermal growth factor receptor monoclonal antibodies with chemotherapy, systemic therapy for advanced or metastatic colorectal cancer: national comprehensive cancer network guidelines for combining, 18S

Anti–vascular endothelial growth factor monoclonal antibodies, clinical use of, in metastatic colorectal cancer, 23S

Aprotinin, benefits and risks of, use during cardiac surgery, 112

Argatroban, successful use of, during the third trimester of pregnancy: case report and review of the literature, 1531

Arginine vasopressin during septic shock, lack of an effect of body mass on the hemodynamic response to, 591

Aripiprazole, diabetic ketoacidosis associated with, 1198

Aspirin resistance: disparities and clinical implications, 999

Atazanavir-ritonavir–based highly active antiretroviral therapy in patients with human immunodeficiency virus, lipid-lowering efficacy and safety after switching to, 323

Atopic dermatitis in caucasian children, association of the histamine *N*-methyltransferase c314t (thr105ile) polymorphism with, 1495

Atorvastatin, effect of, on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects, 1483

Atypical antipsychotics, risk of hospitalization for acute pancreatitis associated with conventional and: a population-based case-control study, 27

- B -

Benign prostatic hyperplasia, anticholinergic therapy for lower urinary tract symptoms associated with, 356

Bicalutamide-associated fulminant hepatotoxicity, 1071
Bisphosphonates, osteonecrosis of the jaw in patients receiving intravenous or oral, 667
Bivalirudin in patients with heparin-induced thrombocytopenia, safety, efficacy, and dosing requirements of, 1115
Bivalirudin, successful use and dosing of, after temporary total artificial heart implantation: a case series, 1413
Blood pressure becomes controlled, reduction in adverse symptoms as, 1104
Blood pressure guidelines, physician adherence to, and its effect on seniors, 843
Blood pressure monitoring, influence of patient characteristics on success of ambulatory, 1341
Bradycardia, efficacy of aminophylline for treatment of recurrent symptomatic, after spinal cord injury, 131
Brain natriuretic peptide concentrations, serial monitoring of, for drug therapy management in patients with chronic heart failure, 343
Business-practice model for pharmacy services in ambulatory settings, developing a, 285
Busulfan, optimal prevention of seizures induced by high-dose, 1502

- C -

Cancer, continued challenges with the use of erythropoiesis-stimulating agents in patients with, perspectives and issues on policy-guided health care, 1S
Capital punishment, issues surrounding lethal injection as a means of, 1429
Carbamazepine to oxcarbazepine, overnight transition from, in children and adolescents, 1211
Cardiovascular comorbidities, optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and, 193
Catecholaminergic effects on ventricular repolarization during inhibition of the rapid component of the delayed rectifier potassium current in a perfused heart model, 1315
Cefazolin and cefepime, an in vivo–in vitro study of, dialytic clearance during high-flux hemodialysis, 977
Cefdinir, nonbloody, red stools from coadministration of, and iron-supplemented infant formulas, 678
Cefepime and cefazolin, an in vivo–in vitro study of, dialytic clearance during high-flux hemodialysis, 977
Cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, in vitro activity of, against extended-spectrum β-lactamase–producing *Klebsiella pneumoniae* and *Escherichia coli*, 295
Cefoxitin, continuous versus intermittent infusion of prophylactic, after colorectal surgery: a pilot study, 1133
Cesium-induced QT-interval prolongation in an adolescent, 1059
Chronic obstructive pulmonary disease, potential role of leukotriene modifiers in the treatment of, 1183
Clarithromycin-repaglinide drug interaction, severe hypoglycemia from, 682
Clinical pharmacist competencies (ACCP), 806
Clinical pharmacy services survey, 2006 national: clinical pharmacy services, collaborative drug management, medication errors, and pharmacy technology, 1
Clinical pharmacy, the definition of (ACCP), 816
Clopidogrel and prasugrel, effect of atorvastatin on the pharmacokinetics and pharmacodynamics of, in healthy subjects, 1483
Clopidogrel desensitization: case report and review of published protocols, 259
Clopidogrel pharmacodynamic response, modulation of (editorial), 1423
Clopidogrel treatment, effects of a waiting period after, before performing coronary artery bypass grafting, 151
Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting, 376
Cognitive impairment, effects of antihypertensive drug treatment on the risk of dementia and, 366
Contraceptives, extended- and continuous-cycle oral, 1033
Contrast medium–induced nephropathy: strategies for prevention, 1140
Corticosteroids, risk of adverse gastrointestinal events from inhaled, 1325

- D -

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases, 1354
Dementia and cognitive impairment, effects of antihypertensive drug treatment on the risk of, 366
Dexmedetomidine, use of, in the pediatric intensive care unit, 51
Diabetes mellitus, determining effective insulin analog therapy based on the individualized needs of patients with type 2, 1299
Diabetes mellitus, effects of pharmacist outpatient interventions on adults with, a systematic review, 421
Diabetes mellitus, optimizing antidiabetic treatment options for patients with type 2, and cardiovascular comorbidities, 193
Diabetes mellitus, third-line agent selection for patients with type 2 , uncontrolled with sulfonylureas and metformin, 506
Diabetes mellitus, type 2 , and heart failure, 170
Diabetic neuropathy, epalrestat: an aldose reductase inhibitor for the treatment of, 646
Dicloxacillin, lack of effect of p-glycoprotein inhibition on renal clearance of, in patients with cystic fibrosis, 883
Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients, 562

Dyslipidemia, antiretroviral-associated, a multimodal, evidence-based approach to achieve lipid targets in the treatment of, case report and review of the literature, 932

- E -

Efavirenz, successful use of reduced-dose, in a patient with human immunodeficiency virus infection: case report and review of the literature, 782
Electrical storm, use of a combination of class III and class Ic antiarrhythmic agents in patients with, 14
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy, 646
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer, 742
Erythropoiesis-stimulating agents in patients with cancer, continued challenges with the use of, perspectives and issues on policy-guided health care, 1S
Erythropoietin, recombinant human, therapy in critically ill Jehovah's Witnesses, 1383
Erythropoietin, use of recombinant human, and risk of severe retinopathy in extremely low-birth-weight infants, 1335
Escitalopram, restless legs syndrome induced by, case report and review of the literature, 271
Estradiol from a topical emulsion, absorption, bioavailability, and partner transfer of, 712
Ethanol detection, ethylglucuronide as a biomarker for, 769
Ethical interactions, pharmacists and industry: guidelines for, 410
Ethical issues related to clinical, translational, and health system research (ACCP), 1421
Ethylglucuronide as a biomarker for ethanol detection, 769
Etravirine, effects of different meal compositions and fasted state on the oral bioavailability of, 1215
Experiential education, ensuring quality (ACCP), 1548
Experiential education, quality (ACCP), 1547
Ezetimibe-simvastatin–induced hepatic failure necessitating liver transplantation, 1188

- F -

Fenofibrate 145-mg nanoparticle tablet formulation, effectiveness of a, compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia, 570
Fosamprenavir-indinavir-ritonavir regimen, pharmacokinetics of an, in patients with human immunodeficiency virus, 74

- G -

Gabapentin as a potential option for treatment of sciatica, 397
Gatifloxacin and levofloxacin, prevalence of and risk factors for dysglycemia in patients receiving, in an outpatient setting, 82
Genetic testing for warfarin dosing? Not yet ready for prime time (editorial), 141
Gentamicin, in vitro activity of cefepime, imipenem, tigecycline, and, alone and in combination, against extended-spectrum β-lactamase–producing *Klebsiella pneumoniae* and *Escherichia coli*, 295
Gingival hyperplasia, association of galactose single-point test levels and phenytoin metabolic polymorphisms with, in patients receiving long-term phenytoin therapy, 35
Glucosamine-warfarin interaction, potential, resulting in increased international normalized ratio: case report and review of the literature and MedWatch database, 540
Gynecomastia possibly induced by rosuvastatin, 549

- H -

Haloperidol, comparison of intranasal administration of, with intravenous and intramuscular administration: a pilot pharmacokinetic study, 875
Heart failure with left ventricular dysfunction, pharmacotherapy for, beyond angiotensin-converting enzyme inhibitors and β-blockers, 920
Heart failure, combination therapy with β-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic, 1523
Heart failure, type 2 diabetes mellitus and, 170
Hemostatic therapy for the treatment of intracranial hemorrhage, 485
Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia, 1401
Heparin-induced thrombocytopenia, safety, efficacy, and dosing requirements of bivalirudin in patients with, 1115
Hepatic encephalopathy, rifaximin for the treatment of, 1019
Hepatitis C, treatment options for patients with, role of pharmacists in optimizing treatment response and managing adverse events, 1151
Hip fractures, proton pump inhibitor use and risk of, in patients without major risk factors, 951
Histamine *N*-methyltransferase c314t (thr105ile) polymorphism, association of the, with atopic dermatitis in caucasian children, 1495
Human papilloma virus vaccination, development of unilateral cervical and supraclavicular lymphadenopathy after, 1194
Hyperglycemia, preventing thiazide-induced, opportunities for clinical pharmacists (editorial), 1425
Hypertension, key articles and guidelines in the management of, 2008 update, 1041
Hypertonic saline, role of, for the management of intracranial hypertension after stroke and traumatic brain injury, 469
Hyperuricemia, evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of, in adults with cancer, 685
Hypothermia, practical pharmacologic aspects of therapeutic, after cardiac arrest, 102

- I -

Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus, 1162

Ibutilide, pharmacokinetics of, in patients with heart failure due to left ventricular systolic dysfunction, 1461

Imipenem, cefepime, tigecycline, and gentamicin, alone and in combination, in vitro activity of, against extended-spectrum β-lactamase–producing *Klebsiella pneumoniae* and *Escherichia coli*, 295

Indinavir-ritonavir-fosamprenavir regimen, pharmacokinetics of an, in patients with human immunodeficiency virus, 74

Industry and pharmacists: guidelines for ethical interactions, 410

Insulin analog therapy, determining effective, based on the individualized needs of patients with type 2 diabetes mellitus, 1299

Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection, 90

Intracranial hemorrhage, hemostatic therapy for the treatment of, 485

Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy, 331

Irritable bowel syndrome, effectiveness of probiotics in the treatment of, 496

Ixabepilone and lapatinib for the treatment of metastatic breast cancer, 1255

- J, K -

Jehovah's Witnesses, recombinant human erythropoietin therapy in critically ill, 1383

Key articles and guidelines in the management of hypertension: 2008 update, 1041

- L -

Laboratory, effects of clinical, choice on study outcome: an interlaboratory evaluation of aminotransferase levels, 453

Lamivudine, short-term safety and tolerability of a once-daily fixed-dose abacavir-, combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study, 314

Lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion, greater immediate gastric acid suppression with, 301

Lapatinib and ixabepilone for the treatment of metastatic breast cancer, 1255

Lethal injection, issues surrounding, as a means of capital punishment, 1429

Leukotriene modifiers, potential role of, in the treatment of chronic obstructive pulmonary disease, 1183

Levetiracetam, rapid dosage titration of, in children, 393

Levofloxacin, prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and, in an outpatient setting, 82

Lorazepam dose threshold, determination of a, for using the osmol gap to monitor for propylene glycol toxicity, 984

- M -

Medication reconciliation program, clinical outcomes of a home-based, after discharge from a skilled nursing facility, 444

Meropenem, steady-state pharmacokinetics and pharmacodynamics of, in hospitalized patients, 691

Methadone enantiomers, pharmacokinetics and pharmacodynamics of, after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects, 863

Methylphenidate, cardiac arrest with pulseless electrical activity associated with, in an adolescent with a normal baseline echocardiogram, 1408

Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC study, 834

Montelukast, pretreatment with albuterol versus, for exercise-induced bronchospasm in children, 287

Multidrug-resistant gram-negative bacilli in North America, the current state of, insights from the Society of Infectious Diseases Pharmacists, 235

Mutism, treatment of selective, focus on selective serotonin reuptake inhibitors, 214

Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia, 281

Mycophenolate mofetil, depressive disorder associated with, 136

- N -

Nelfinavir systemic exposure, significant decrease in, after omeprazole coadministration in healthy subjects, 42

Nephropathy, contrast medium–induced, strategies for prevention, 1140

Nephropathy, new therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric, 125

Neuroleptic malignant syndrome, atypical, diagnostic controversies and considerations, 530

Neuroleptic malignant syndrome, olanzapine-associated, in a patient receiving concomitant rivastigmine therapy, 403

Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia, 1374

Nonsteroidal antiinflammatory drugs, management of chronic nonmalignant pain with, 788

- O -

Off-label prescribing, prioritizing future research on, results of a quantitative evaluation, 1443

Olanzapine-associated neuroleptic malignant

syndrome in a patient receiving concomitant rivastigmine therapy, 403
Ondansetron-induced aminotransferase level elevation: case report and review of the literature, 1542
Opioid requirements and analgesic response, comparison of, in opioid-tolerant versus opioid-naïve patients after total knee arthroplasty, 1453
Osmol gap, determination of a lorazepam dose threshold for using the, to monitor for propylene glycol toxicity, 984
Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates, 667
Oxcarbazepine, overnight transition from carbamazepine to, in children and adolescents, 1211

- P -

Pain, management of chronic nonmalignant, with nonsteroidal antiinflammatory drugs, 788
Paliperidone extended-release for the treatment of schizophrenia, 1283
Pancreatitis, risk of hospitalization for acute, associated with conventional and atypical antipsychotics: a population-based case-control study, 27
Patent ductus arteriosus, ibuprofen lysine for the prevention and treatment of, 1162
P-glycoprotein inhibition, lack of effect of, on renal clearance of dicloxacillin in patients with cystic fibrosis, 883
Pharm.D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research, 821
Pharmacists and industry: guidelines for ethical interactions, 410
Pharmacoeconomic and outcomes research fellowship training programs, guidelines for (ACCP), 1552
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?, 755
Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use, 992
Pharmacotherapy residency, what is a, benefits of a 24-month program (editorial), 819
Pharmacy vision and leadership: revisiting the fundamentals, 1437
Phenytoin, therapeutic drug monitoring of, in critically ill patients, 1391
Pneumonia protocol, impact of an institution-specific hospital-acquired, on the appropriateness of antibiotic therapy and patient outcomes, 852
Posaconazole, pharmacokinetics of oral, in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome, 1223
Posttraumatic stress disorder sleep disturbances, prazosin for the treatment of, 656
Prasugrel and clopidogrel, effect of atorvastatin on the pharmacokinetics and pharmacodynamics of, in healthy subjects, 1483
Prazosin for the treatment of posttraumatic stress disorder sleep disturbances, 656
Premenstrual symptoms in women using oral contraceptives, comparison of scales for evaluating, 576
Probiotics, effectiveness of, in the treatment of irritable bowel syndrome, 496
Propacetamol, effect of intravenous, on blood pressure in febrile critically ill patients, 1205
Propofol-related infusion syndrome in intensive care patients, 250
Protein intake, potential interaction between warfarin and high dietary, 536
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors, 951
Publication, research, by pharmacist authors in major medical journals: changes over a 10-year interval, 584

- R -

Rasburicase, evaluation of a single fixed dose of, 7.5 mg for the treatment of hyperuricemia in adults with cancer, 685
Renin-angiotensin system inhibitors, new therapeutic strategies with combined, for pediatric nephropathy, 125
Repaglinide-clarithromycin drug interaction, severe hypoglycemia from, 682
Research publication by pharmacist authors in major medical journals: changes over a 10-year interval, 584
Research, Pharm.D. pathways to biomedical, the National Institutes of Health special conference on pharmacy research, 821
Restless legs syndrome induced by escitalopram: case report and review of the literature, 271
Retinopathy, use of recombinant human erythropoietin and risk of severe, in extremely low-birth-weight infants, 1335
Rifabutin and voriconazole, concomitant use of, in a patient with multiple infections, 1076
Rifaximin for the treatment of hepatic encephalopathy, 1019
Ritonavir-atazanavir–based highly active antiretroviral therapy in patients with human immunodeficiency virus, lipid-lowering efficacy and safety after switching to, 323
Ritonavir-fosamprenavir-indinavir regimen, pharmacokinetics of an, in patients with human immunodeficiency virus, 74
Rivastigmine therapy, olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant, 403
Rosuvastatin, gynecomastia possibly induced by, 549

- S -

Scared to death (editorial), 1311
Schizophrenia, the case for autoimmunity in the etiology of, 730
Sciatica, gabapentin as a potential option for treatment of, 397

Seizures induced by high-dose busulfan, optimal prevention of, 1502
Simvastatin, safety and efficacy of, for the treatment of dyslipidemia in human immunodeficiency virus–infected patients receiving efavirenz-based highly active antiretroviral therapy, 913
Simvastatin-ezetimibe–induced hepatic failure necessitating liver transplantation, 1188
Sirolimus and voriconazole, concurrent administration of, a pilot study assessing safety and approaches to appropriate management, 719
Skeletal muscle relaxants, 207
Statin therapy, safety of, in patients with preexisting liver disease, 522
Statin therapy, switching, using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients, 553
Stimulants, nonmedical use of prescription, among college students: associations with attention-deficit–hyperactivity disorder and polydrug use, 156
Sunitinib-related fulminant hepatic failure: case report and review of the literature, 1066

- T -

Telavancin versus vancomycin, cost-effectiveness of, for treatment of complicated skin and skin structure infections, 1471
Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections, 458
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma, 406
Therapeutic drug monitoring of phenytoin in critically ill patients, 1391
Thiazide-induced hyperglycemia, preventing, opportunities for clinical pharmacists, 1425
Thromboembolism, antidepressant drug use and risk of venous, 144
Tigecycline, cefepime, imipenem, and gentamicin, alone and in combination, in vitro activity of, against extended-spectrum β-lactamase–producing *Klebsiella pneumoniae* and *Escherichia coli*, 295
Tigecycline-warfarin drug interaction, evaluation of a potential, 895
Tobramycin concentrations, elevated serum, after treatment with tobramycin inhalation in a preterm infant, 939
Tuberculosis, treatment of extensively drug-resistant, and role of the pharmacist, 1243

- U, V -

Uridine diphosphate glucuronosyltransferase 1A1 polymorphisms, pharmacogenetic testing for, are we there yet?, 755
Vancomycin prophylaxis, economic benefit of appropriate timing of, in patients undergoing cardiovascular surgery, 699
Vancomycin versus telavancin, cost-effectiveness of, for treatment of complicated skin and skin structure infections, 1471
Vitamin D supplementation to prevent falls in the elderly: evidence and practical considerations, 225
Voriconazole and rifabutin, concomitant use of, in a patient with multiple infections, 1076
Voriconazole and sirolimus, concurrent administration of, a pilot study assessing safety and approaches to appropriate management, 719
Voriconazole, oral, for empiric antifungal treatment in patients with uncomplicated febrile neutropenia, 58

- W -

Warfarin and high dietary protein intake, potential interaction between, 536
Warfarin-antiretroviral therapy drug interaction, possible, 945
Warfarin dosages, pharmacodynamics of uniform versus nonuniform, 707
Warfarin dosing, genetic testing for? Not yet ready for prime time, 141
Warfarin pharmacogenetics, 1084
Warfarin resistance after total gastrectomy and Roux-en-Y esophagojejunostomy, 1537
Warfarin resistance, vitamin K–independent, after concurrent administration of warfarin and continuous enteral nutrition, 308
Warfarin therapy, thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on, the low INR study, 960
Warfarin-tigecycline drug interaction, evaluation of a potential, 895
Warfarin, discrepancies in identification of major bleeding events in patients taking, 1098
Warfarin: an old drug but still interesting (editorial), 1081
Warfarin-glucosamine interaction, potential, resulting in increased international normalized ratio: case report and review of the literature and MedWatch database, 540